NEW YORK – PCR testing is the gold standard for molecular tests and continues to be a major focus for test developers during the ongoing COVID-19 pandemic, but the lack of portability and a complicated workflow are major drawbacks often cited as hindrances to the technology.
Diagnostic startup Visby Medical, however, has a PCR technology to overcome those barriers and has had its tech acknowledged by the National Institutes of Health – to the tune of $19 million.